ERBB2 and breast cancer: High levels of immune infiltrate have also been observed in early-stage HER2+ breast cancers, and associations with prognosis and prediction have been reported.12,16,19,22,24 Immunotherapy is therefore currently being investigated in the setting of metastatic HER2+ disease.